<DOC>
	<DOCNO>NCT00403000</DOCNO>
	<brief_summary>RATIONALE : Dutasteride may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study well dutasteride work treat patient recurrent prostate cancer respond androgen-deprivation therapy .</brief_summary>
	<brief_title>Dutasteride Treating Patients With Recurrent Prostate Cancer That Did Not Respond Androgen-Deprivation Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate time disease progression patient recurrent prostate cancer progress androgen-deprivation therapy treat dutasteride . - Evaluate toxicity dutasteride patient . Secondary - Evaluate serum prostate-specific antigen ( PSA ) level objective radiographic response rate patient treat dutasteride . - Determine survival patient treat dutasteride . - Determine quality life patient treat dutasteride . OUTLINE : Patients receive oral dutasteride daily disease progression unacceptable toxicity . Quality life assess baseline every 3 month thereafter . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 27 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis prostate cancer Asymptomatic progressive disease despite androgendeprivation therapy Progression must occur androgendeprivation therapy comprise orchiectomy luteinizing hormonereleasing hormone ( LHRH ) analogue without antiandrogen AND antiandrogen withdrawal Concurrent LHRH monotherapy ( i.e. , LHRH analog , leuprolide acetate goserelin ) require patient undergo prior bilateral orchiectomy assure testicular androgen suppression Recurrent disease , indicate least 1 follow : Prostatespecific antigen ( PSA ) baseline ≥ 2.0 ng/mL Biopsyconfirmed local recurrence Increase size measurable lesion radiographic study New lesion nuclear bone scan Two successive increase serum PSA measure least 1 week apart PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 12 week Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL Bilirubin ≤ 2.0 mg/dL SGOT ≤ 4 time upper limit normal Creatinine ≤ 2.0 mg/dL Fertile patient must use effective contraception 3 month completion study therapy PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 28 day since prior radiotherapy recover At least 28 day since prior flutamide OR least 42 day since prior bicalutamide nilutamide Patients previously progress despite antiandrogen withdrawal start antiandrogens without reduction serum PSA eligible without require 28 42day washout interval antiandrogen withdrawal No prior systemic therapy , except androgendeprivation therapy ( i.e. , orchiectomy LHRH analogue ) antiandrogens Surgery , brachytherapy , externalbeam radiotherapy , cryotherapy consider systemic therapy No concurrent anticancer therapy No concurrent use follow : Finasteride Other investigational 5αreductase inhibitor Anabolic steroid Alphareceptor blocker ( e.g. , indoramin , tamsulosin hydrochloride , prazosin , terazosin , alfuzosin hydrochloride , doxazosin ) Drugs antiandrogenic property ( e.g. , spironolactone , flutamide , bicalutamide , cimetidine , ketoconazole , metronidazole , progestational agent ) Products contain selenium ≥ 75 mcg vitamin E ≥ 100 IU Saw palmetto EG6761 No concurrent radiotherapy , include palliative radiotherapy pain control</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>recurrent prostate cancer</keyword>
</DOC>